Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents

Bibliography

• JACOBSOHN DA: Novel therapeutics for the treatment of graft versus host disease. Expert Opin. Investig. Drugs (2002) 11(9):1271–1280.
   PubMed Web of Science ®Google Scholar
• GARBER K: Rapamycin's resurrection: a new way to target the cancer cell cycle. J. Natl. Cancer Inst. (2001) 93(20): 1517–1519.
   PubMed Web of Science ®Google Scholar
• LA ROSEE P, O'DWYER ME, DRUKER BJ: Insights from preclinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukaemia: a translational perspective. Leukemia (2002) 16(7):1213–1219.
   PubMed Web of Science ®Google Scholar
• YUFU Y, NISHIMURA J, NAWATA H: High constitutive expression of heat-shock protein 90 alpha in human acute leukaemia cells. Leak. Res. (1992) 16(6-7):597–605.
   PubMed Web of Science ®Google Scholar
• OPPERMANN H, LEVINSON AD, LEVINTOW L, VARMUS HE, BISHOP JM, KAWAI S: Two cellular proteins that immunoprecipitate with the transforming protein of Rous sarcoma virus. Virology (1992) 113(2):736–751.
   Web of Science ®Google Scholar
• •First paper to describe association of Hsp90 with a kinase.
   Google Scholar
• ZIEMIECKI A, CATELLI MG, JOAB I, MONCHARMONT B: Association of the heat-shock protein hsp90 with steroid hormone receptors and tyrosine kinase oncogene products. Biochem. Biophys. Res. Commun. (1986) 138(3):1298–1307.
   PubMed Web of Science ®Google Scholar
• •Description of Hsp90 association with steroid receptors.
   Google Scholar
• XU Y, LINDQUIST S: Heat-shock protein hsp90 governs the activity of pp60v-src kinase. Proc. Nati Acad. Sd. USA. (1993) 90(15):7074–7078.
   PubMed Web of Science ®Google Scholar
• STANCATO LF, SILVERSTEIN AM, OWENS-GRILLO JK, CHOW YH, JOVE R, PRATT WB: The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signalling without disrupting formation of signalling complexes or reducing the specific enzymatic activity of Raf kinase. J. Biol. Chem. (1997) 272(7):4013–4020.
   PubMed Web of Science ®Google Scholar
• SRIVASTAVA PK, MAKI RG: Stress-induced proteins in immune response to cancer. Curc Top. Microbial. Immunol. (1991) 167:109–123.
   PubMed Web of Science ®Google Scholar
• CIOCCA DR, FUQUA SA, LOCK-LIM S, TOFT DO, WELCH WJ, MCGUIRE W: Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res. (1992) 52(13):3648–3654.
   PubMed Web of Science ®Google Scholar
• WHITESELL L, SHIFRIN SD, SCHWAB G, NECKERS L: Benzoquinonoid ansamycins possess selective tumouricidal activity unrelated to src kinase inhibition. Cancer Res. (1992) 52(7):1721–1728.
   PubMed Web of Science ®Google Scholar
• WHITESELL L, MIMNAUGH EG, DE COSTA B, MYERS CE, NECKERS LM: Inhibition of heat-shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA (1994) 91(18):8324–8328.
   PubMed Web of Science ®Google Scholar
• ••First paper to identify Hsp90 as themolecular target of benzoquinone ansamycins.
   Google Scholar
• FERRARINI M, HELTAI S, ZOCCHI MR, RUGARLI C: Unusual expression and localization of heat-shock proteins in human tumour cells. hat. J. Cancer (1992) 51(4):613–619.
   PubMed Web of Science ®Google Scholar
• BLAGOSKLONNY MV, TORETSKY J, BOHEN S, NECKERS L: Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc. Natl. Acad. Sd. USA. (1996) 93(16):8379–8383.
   PubMed Web of Science ®Google Scholar
• SATO S, FUJITA N, TSURUO T: Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. ScL USA. (2000) 97(20):10832–10837.
   PubMed Web of Science ®Google Scholar
• HOSTEIN I, ROBETSON D, DISTEFANO F, WORKMAN P, CLARKE PA: Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res. (2001) 6(10):4003–4009.
   Google Scholar
• SCHULTE TW, BLAGOSKLONNY MV, ROMANOVA L et at.: Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf- 1-MEK-mitogen-activated protein kinase signalling pathway. Ma Cell. Biol. (1996) 16(10):5839–5845.
   Web of Science ®Google Scholar
• AN WG, SCHULTE TW, NECKERS LM: The heat-shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. (2000) 11(7):355–360.
   PubMedGoogle Scholar
• •This and the following paper describe the dependence of Bcr-Abl kinase on Hsp90 for stability and function.
   Google Scholar
• SHIOTSU Y, NECKERS LM, WORTMAN I et al.: Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukaemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood (2000) 96(6):2284–2291.
   Google Scholar
• BONVINI P, GASTALDI T, FALINI B, ROSOLEN A: Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90- client tyrosine kinase: downregulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino-17-demethoxygeldanamycin. Cancer Res. (2002) 62(5):1559–1566.
   PubMed Web of Science ®Google Scholar
• MILLER P, SCHNUR RC, BARBACCI E, MOYER MP, MOYER JD: Binding of benzoquinoid ansamycins to p100 correlates with their ability to deplete the erbB2 gene product p185. Biochem. Biophys. Res. Commun. (1994) 201(3):1313–1319.
   PubMed Web of Science ®Google Scholar
• ••This and the following two papers document the Hsp90 dependence of ErbB2 (Her-2/Neu) tyrosine kinase.
   Google Scholar
• MILLER P, DIORIO C, MOYER M et al.: Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins. Cancer Res. (1994) 54(10):2724–2730.
   PubMed Web of Science ®Google Scholar
• CHAVANY C, MIMNAUGH E, MILLER P et al: p185erbB2 binds to GRP94 in viva Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. Biol. Chem. (1996) 271(9):4974–4977.
   Web of Science ®Google Scholar
• STEPAN OVA L, LENG X, PARKER SB, HARPER JW. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev. (1996) 10(12):1491–1502.
   PubMed Web of Science ®Google Scholar
• •Describes the involvement of p50Cdc37 in Hsp90 complexes that associate with kinases.
   Google Scholar
• ALIGUE R, AKHAVAN-NIAK H, RUSSELL P: A role for Hsp90 in cell cycle control: Weel tyrosine kinase activity requires interaction with Hsp90. EMBO (1994) 13(24):6099–6106.
   PubMed Web of Science ®Google Scholar
• MINET E, MOTTET D, MICHEL G et al.: Hypcoda-induced activation of HIF-1: role of HIF- lalpha-Hsp90 interaction. FEBS Lett. (1999) 460(2):251–256.
   PubMed Web of Science ®Google Scholar
• ISAACS JS, JUNG YJ, MIMNAUGH EG, MARTINEZ A, CUTTITTA F, NECKERS LM: Hsp90 regulates a VHL-independent HIF- lalpha degradative pathway. I Biol. Chem. (2002) 277(33):29936–29944.
   Web of Science ®Google Scholar
• FANG Y, FLISS AE, ROBINS DM, CAPLAN A: Hsp90 regulates androgen receptor hormone binding affinity in vivo. J. Biol. Chem. (1996) 271(45): 28697–28702.
   PubMed Web of Science ®Google Scholar
• PRATT WB, TOFT DO: Steroid receptor interactions with heat-shock protein and immunophilin chaperones. Endocr. Rev (1997) 18(3):306–360.
   PubMed Web of Science ®Google Scholar
• •An excellent review of the interaction of steroid hormone receptors with molecular chaperones.
   Google Scholar
• SEGNITZ B, GEHRING U: The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin. J. Biol. Chem. (1997) 272(30): 18694–18701.
   PubMed Web of Science ®Google Scholar
• BAGATELL R, KHAN O, PAINE-MURRIETA G, TAYLOR CW, AKINAGA S, WHITESELL L: Destabilization of steroid receptors by heat-shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin. Cancer Res. (2001) 7(7)2076–2084.
   PubMed Web of Science ®Google Scholar
• HAENDLER B, SCHUTTKE I, SCHLEUNING WD: Androgen receptor signalling: comparative analysis of androgen response elements and implication of heat-shock protein 90 and 14-3-3eta. Ma Cell. Endocrinol (2001) 173(1-2):63–73.
   PubMed Web of Science ®Google Scholar
• HOLT SE, AISNER DL, BAUR J et al.: Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev. (1999) 13(7):817–826.
   PubMed Web of Science ®Google Scholar
• GRENERT JP, SULLIVAN WP, FADDEN P et al.: The amino-terminal domain of heat-shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J. Biol. Chem. (1997) 272(38):23843–23850.
   PubMed Web of Science ®Google Scholar
• ••This and the following two papers identifythe GA binding site on Hsp90 to be an amino terminal nucleotide-binding pocket that regulates Hsp90 conformation.
   Google Scholar
• STEBBINS CE, RUSSO AA, SCHNEIDER C, ROSEN N, HARTL FU, PAVLETICH NP: Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumour agent. Cell (1997) 89(2):239–250.
   PubMed Web of Science ®Google Scholar
• PRODROMOU C, ROE SM, O'BRIEN R, LADBURY JE, PIPER PW, PEARL LH: Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell (1997) 90(1):65–75.
   Google Scholar
• CSERMELY P, KAJTAR J, HOLLOSI M et al.: ATP induces a conformational change of the 90-kDa heat-shock protein (hsp90). J. Biol. Chem. (1993) 268(3):1901–1907.
   PubMed Web of Science ®Google Scholar
• •An early paper suggesting that Hsp90 binds ATP and that this has consequences for chaperone function.
   Google Scholar
• PANARETOU B, PRODROMOU C, ROE SM et al.: ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in viva EMBO (1998) 17(16):4829–4836.
   PubMed Web of Science ®Google Scholar
• GRENERT JP, JOHNSON BD, TOFT DO: The importance of ATP binding and hydrolysis by hsp90 in formation and function of protein heterocomplexes. I Biol. Chem. (1999) 274(25):17525–17533.
   Web of Science ®Google Scholar
• SCHEIBEL T, BUCHNER J: The Hsp90 complex-a super-chaperone machine as a novel drug target. Biochem. Pharmacol (1998) 56(6):675–682.
   PubMed Web of Science ®Google Scholar
• •A nice review of the mechanisms of the Hsp90 chaperone machine.
   Google Scholar
• HERNANDEZ MP, CHADLI A, TOFT DO: HSP40 binding is the first step in the HSP90 chaperoning pathway for the progesterone receptor. Biol. Chem. (2002) 277(14):11873–11881.
   Web of Science ®Google Scholar
• HERNANDEZ MP, SULLIVAN WP, TOFT DO: The assembly and intermolecular properties of the hsp70-Hop-hsp90 molecular chaperone complex. J. Biol. Chem. (2002) 277(41):38294–38304.
   PubMed Web of Science ®Google Scholar
• YOUNG JC, HARTL FU: Polypeptide release by Hsp90 involves ATP hydrolysis and is enhanced by the cochaperone p23. EMBO J. (2000) 19(21):5930–5940.
   PubMed Web of Science ®Google Scholar
• SILIGARDI G, PANARETOU B, MEYER P et al: Regulation of Hsp90 ATPase activity by the cochaperone Cdc37p/p50cdc37. J. Biol. Chem. (2002) 277(23): 20151–20159.
   PubMed Web of Science ®Google Scholar
• MCLAUGHLIN SH, SMITH HW, JACKSON SE: Stimulation of the weak ATPase activity of human hsp90 by a client protein. J. Ma Biol. (2002) 315(4)787–798.
   Web of Science ®Google Scholar
• SCHNEIDER C, SEPP-LORENZINO L, NIMMESGERN E et al.: Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc. Natl. Acad. Sci. USA (1996) 93(25):14536–14541.
   PubMed Web of Science ®Google Scholar
• ••The first paper to suggest that Hsp90 canpromote both the stability and the degradation of its client proteins and that GA shifts this balance towards degradation.
   Google Scholar
• CONNELL P, BALLINGER CA, JIANG J et al: The cochaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell Biol. (2001) 3(1):93–96.
   PubMed Web of Science ®Google Scholar
• •Identification of the first chaperone-dependent E3 ubiquitin ligase.
   Google Scholar
• MEACHAM GC, PATTERSON C, ZHANG W, YOUNGER JM, CYR DM: The Hsc70 cochaperone CHIP targets immature CFTR for proteasomal degradation. Nat. Cell Biol. (2001) 3(1):100–105.
   PubMed Web of Science ®Google Scholar
• XU W, MARCU M, YUAN X, MIMNAUGH E, PATTERSON C, NECKERS L: Chaperone-dependent E3 ubiquitin ligase CHIP mediates a novel degradative pathway for c-ErbB2/Neu. Proc. Natl. Acad. Sci. USA (2002) 99(20):12847–12852.
   PubMed Web of Science ®Google Scholar
• •Demonstration that CHIP can cooperate with GA to promote degradation of ErbB2.
   Google Scholar
• CHIOSIS G, ROSEN N, SEPP-LORENZINO L: LY-294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg. Med. Chem. Lett. (2001) 11(7):909–913.
   PubMed Web of Science ®Google Scholar
• SCHULTE TW, NECKERS LM: The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother: Pharmacol (1998) 42(4):273–279
   PubMed Web of Science ®Google Scholar
• •A paper showing that the clinically tolerable GA derivative, 17-AAG, binds to Hsp90 and has activity similar to that of GA.
   Google Scholar
• KELLAND LR, SHARP SY, ROGERS PM, MYERS TG, WORKMAN P: DT-Diaphorase expression and tumour cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90. J. Nail. Cancer Inst. (1999) 91(22):1940–1949.
   PubMed Web of Science ®Google Scholar
• AGNEW EB, WILSON RH, GREM JL, NECKERS L, BI D, TAKIMOTO CH: Measurement of the novel antitumour agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography. J.Chromatogr: B Biomed. ScL Appl. (2001) 755(1-2):237–243.
   PubMed Web of Science ®Google Scholar
• SRETHAPAKDI M, LIU F, TAVORATH R, ROSEN N: Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res. (2000) 60(14):3940–3946.
   PubMed Web of Science ®Google Scholar
• BLAGOSKLONNY MV, FOJO T, BHALLA KN et al.: The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukaemia cells to cytotoxic chemotherapy. Leukaemia (2001) 15(10):1537–1543.
   PubMed Web of Science ®Google Scholar
• NIMMANAPALLI R, O'BRYAN E, BHALLA K: Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr- Abl-positive human leukemic blasts. Cancer Res. (2001) 61(5):1799–1804.
   PubMed Web of Science ®Google Scholar
• GORRE ME, ELLWOOD-YEN K, CHIOSIS G, ROSEN N, SAWYERS CL: BCR-ABL point mutants isolated from patients with 5TI571-resistant chronic myeloid leukaemia remain sensitive to inhibitors of the BCR-ABL chaperone heat-shock protein 90. Blood (2002) 100(8):3041–3044.
   PubMed Web of Science ®Google Scholar
• •A paper showing that Gleevec-resistant Bcr-Abl protein remains sensitive to 17-AAG.
   Google Scholar
• SOLIT D et al.: 17-allyl-amino-geldanamycin induces the degradation of AR and HERZ in prostate cancer xenograft tumours and inhibits their growth. Proceedings of the AACR (2001) 42:363.
   Google Scholar
• GORRE ME, MOHAMMED M, ELLWOOD K et at: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 293(5531):876–880.
   PubMed Web of Science ®Google Scholar
• MUNSTER PN, BASSO A, SOLIT D, NORTON L, ROSEN N: Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17- allylamino, 17-demethoxygeldanamycin: sequence and tumour biology matters, Clin. Cancer Res, (2001) 7:2155-2158. Cilia. Cancer Res. (2001) 7(8):2228–2236.
   PubMed Web of Science ®Google Scholar
• NGUYEN DM, LORANG D, CHEN GA, STEWART JH 4th, TABIBI E, SCHRUMP DS: Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: M vitro and in vivo analysis. Ann. Thorac. Surg. (2001) 72(2):371–378.
   PubMed Web of Science ®Google Scholar
• NGUYEN DM, CHEN A, MIXON A, SCHRUMP DS: Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin. I Thorac. Cardiovasc. Surg. 118(5):908–915.
   Web of Science ®Google Scholar
• HOROWITZ JM, PARK SH, BOGENMANN E et al.: (1990) Frequent inactivation of the retinoblastoma antioncogene is restricted to a subset of human tumour cells. Proc. Nail. Acad. Sci. USA (1999) 87(7):2775–2779.
   Web of Science ®Google Scholar
• LAI SL, BRAUCH H, KNUTSEN T et al.:Molecular genetic characterization of neuroendocrine lung cancer cell lines. AntiCancer Res.(1995) 15(2):225–232.
   Google Scholar
• ZHONG H, DE MARZO AM, LAUGHNER E et al.: Overexpression of hypcoda-inducible factor-lalpha in common human cancers and their metastases. Cancer Res. (1999) 59(22):5830–5835.
   PubMed Web of Science ®Google Scholar
• KUROSE K, ZHOU XP, ARAKI T, CANNISTRA SA, MAHER ER, ENG C: Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am. J. Pathol (2001) 158(6):2097–2106.
   PubMed Web of Science ®Google Scholar
• SHARMA SV, AGATSUMA T, NAKANO H: Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene (1998) 16(20):2639–2645.
   PubMed Web of Science ®Google Scholar
• ••This and the following two papersdemonstrate that radicicol also binds to the amino terminal nucleotide pocket in Hsp90 and has biologic activity similar to GA.
   Google Scholar
• SCHULTE TW, AKINAGA S, SOGA S et al.: Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones (1998) 3(2):100–108.
   PubMed Web of Science ®Google Scholar
• ROE SM, PRODROMOU C, O'BRIEN R, LADBURY JE, PIPER PW, PEARL LH: Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumour antibiotics radicicol and geldanamycin. J. Med. Chem. (1999) 42(2):260–266.
   PubMed Web of Science ®Google Scholar
• MARCU MG, CHADLI A, BOUHOUCHE I, CATELLI M, NECKERS LM: The heat-shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. j. Biol. Chem. (2000) 275(47):37181–37186.
   PubMed Web of Science ®Google Scholar
• ••This and the following paper describe a novel ATP binding site in the C-terminus of Hsp90 as the binding site for a third class of Hsp90 inhibitor, novobiocin.
   Google Scholar
• MARCU MG, SCHULTE TW, NECKERS L: Novobiocin and related coumarins and depletion of heat-shock protein 90- dependent signalling proteins. J. Natl. Cancer Inst. (2000) 92(3):242–248.
   PubMed Web of Science ®Google Scholar
• CHIOSIS G, TIMAUL MN, LUCAS B et al.: A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. (2001) 8(3):289–299.
   PubMed Web of Science ®Google Scholar
• JOHNSON BD, CHADLI A, FELTS SJ, BOUHOUCHE I, CATELLI MG, TOFF DO: Hsp90 chaperone activity requires the full-length protein and interaction among its multiple domains. I Biol. Chem. (2000) 275(42):32499–32507.
   Web of Science ®Google Scholar
• PEARL LH, PRODROMOU C: Structure and in vivo function of Hsp90. Can: Opin. Smart. Biol. (2000) 10(1):46–51.
   PubMed Web of Science ®Google Scholar
• PEARL LH, PRODROMOU C: Structure, function and mechanism of the Hsp90 molecular chaperone. Adv. Protein Chem. (2001) 59:157–186
   PubMedGoogle Scholar
• OWEN BA, SULLIVAN WP, FELTS SJ, TOFT DO: Regulation of heat-shock protein 90 ATPase activity by sequences in the carboxyl terminus. Biol. Chem. (2002) 277(9):7086–7091.
   Web of Science ®Google Scholar
• SOTI C, RACZ A, CSERMELY P: A Nucleotide-dependent molecular switch controls ATP binding at the C- terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket. j. Biol. Chem. (2002) 277(9):7066–7075.
   PubMed Web of Science ®Google Scholar
• ••A further analysis of the C-terminal ATPbinding domain of Hsp90.
   Google Scholar
• ITOH H, OGURA M, KOMATSUDA A, WAKUI H, MIURA AB, TASHIMA Y: A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90. Biochem. (1999) 343:697–703.
   Google Scholar
• SLEPIAN MJ, MASSIA SP, WHITESELL L: Preconditioning of smooth muscle cells via induction of the heat shock response limits proliferation following mechanical injury. Biochem. Biophys. Res. Commun. (1996) 225(2):600–607.
   PubMed Web of Science ®Google Scholar
• CONDE AG, LAU SS, DILLMANN WH, MESTRIL R: Induction of heat-shock proteins by tyrosine kinase inhibitors in rat cardiomyocytes and myogenic cells confers protection against simulated ischaemia. Ma Cell. Cardiol (1997) 29(7):1927–1938.
   PubMed Web of Science ®Google Scholar
• ALI A, BHARADWAJ S, O'CARROLL R, OVSENEK N: HSP90 interacts with and regulates the activity of heat shock factor 1 in Xenopus oocytes. MM. Cell. Biol. (1998) 18(9):4949–4960.
   Web of Science ®Google Scholar
• KIM HR, KANG HS, KIM HD: Geldanamycin induces heat-shock protein expression through activation of HSF1 in K562 erythroleukemic cells. IUBMB Life. (1999) 48(4):429–433.
   PubMed Web of Science ®Google Scholar
• XIAO N, CALLAWAY CW, LIPINSKI CA, HICKS SD, DEFRANCO DB: Geldanamycin provides post-treatment protection against glutamate- induced oxidative toxicity in a mouse hippocampal cell line. 1 Neurochem. (1999) 72(1):95–101.
   PubMed Web of Science ®Google Scholar
• GUO Y, GUETTOUCHE T, FENNA M et al.: Evidence for a mechanism of repression of heat shock factor 1 transcriptional activity by a multichaperone complex. j. Biol. Chem. (2001) 276(49):45791–45799.
   PubMed Web of Science ®Google Scholar
• LU A, RAN R, PARMENTIER-BATTEUR S, NEE A, SHARP FR: Geldanamycin induces heat-shock proteins in brain and protects against focal cerebral ischaemia. Neurochem. (2002) 81(2):355–364.
   PubMed Web of Science ®Google Scholar
• BAGATELL R, PAINE-MURRIETA GD, TAYLOR CW et al.: Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin. Cancer Res. (2000) 6(8):3312–3318.
   PubMed Web of Science ®Google Scholar
• RUTHERFORD SL, LINDQUIST S: Hsp90 as a capacitor for morphological evolution. Nature (1998) 396(6709):336–342.
   PubMed Web of Science ®Google Scholar
• ••This and the following paper present evidence supporting the hypothesis that Hsp90 may play a role in evolution.
   Google Scholar
• QUEITSCH C, SANGSTER TA, LINDQUIST S: Hsp90 as a capacitor of phenotypic variation. Nature (2002) 417(6889):618–624.
   PubMed Web of Science ®Google Scholar
• MIMNAUGH EG, WORLAND PJ, WHITESELL L, NECKERS LM: Possible role for serine/threonine phosphorylation in the regulation of the heteroprotein complex between the hsp90 stress protein and the pp60v-src tyrosine kinase.j. Biol. Chem. (1995) 270(48):28654–28659.
   Web of Science ®Google Scholar
• ZHAO YG, GILMORE R, LEONE G, COFFEY MC, WEBER B, LEE PW: Hsp90 phosphorylation is linked to its chaperoning function. Assembly of the reovirus cell attachment protein. .1 Biol. Chem. (2001) 276(35):32822–32827.
   Web of Science ®Google Scholar